Ronde-Cel Shows 77% Complete Response Rate in 3L+ Lymphoma Ahead of ASH
LYEL sits 63% above its 52-week low of $7.195.
Summary
Lyell disclosed updated ronde-cel data ahead of ASH 2026 (Dec 12-15), covering more than 80 patients across the pivotal 3L+ PiNACLE trial and the Phase 1/2 2L cohort. In 3L+, 44 response-evaluable patients showed a 91% overall response rate and 77% complete response rate, with median PFS not reached and estimated 24-month PFS of 54%. The 2L cohort posted 95% ORR and 76% CR among 37 evaluable patients. Safety looks clean on CRS — no Grade ≥3 events in either cohort — though Grade ≥3 ICANS hit 9% in both. This lands the same day as the $80M private placement at $10.77 per share, which funds the ronde-cel push; the data support that raise rather than change the story, and shares rose 35%. Full pivotal PiNACLE data are expected mid-2027, with BLA submission in the second half of 2027.
At the time of this announcement, LYEL was trading at $11.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $263.9M. The 52-week trading range was $7.20 to $45.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.